CD4 and neoplasm: IL-33/ST2 signaling suppresses IL-17A production and potentially promotes the conversion of IL-17-producing CD4+ T cell types to IL-17-negative (RORγt−) ST2+ FOXP3+ Treg cells, modifying the inflammatory signals within the tumour microenvironment to promote CRC (100).